$14.07
Today
as of Sep 4, 16:46 ET
Last 30 days
Recent Press Releases & News
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Bioventus (BVS) Q2 2026 Earnings Call Transcript
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings
Overview
52-week range
$6.25
$16
81% of range
Avg surprise (last 3)
+31.8%
Avg reaction (last 2)
-4.8%
50% positive
Latest IV / EM
143%
EM ±22.4% · $15 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Sat Jun 27, 2026 | Jun 2026 | $0.47 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $0.15 | $0.09 | +66.7% | +87.5% | +2.2% | earnings |
| Sat Sep 27, 2025 | Sep 2025 | $0.05 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.21 | $0.22 | -4.5% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $0.08 | $0.06 | +33.3% | — | -11.8% | earnings |
| Sat Sep 28, 2024 | Sep 2024 | $-0.08 | — | — | — | — | financials |
| Sat Jun 29, 2024 | Jun 2024 | $-0.40 | — | — | — | — | financials |
| Sat Mar 30, 2024 | Mar 2024 | $-0.08 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.12 | — | — | — | — | financials |
| Sat Jul 1, 2023 | Jul 2023 | $-0.06 | — | — | — | — | financials |
| Sat Apr 1, 2023 | Apr 2023 | $-2.24 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $153M | $132M | — | $139M | $148M | $124M | — | $139M |
| Cost of revenue | $48M | $41M | — | $44M | $46M | $41M | — | $45M |
| Gross profit | $106M | $91M | — | $94M | $102M | $83M | — | $94M |
| Operating income | $19M | $8M | — | $11M | $18M | $5M | — | $4M |
| Net income | $33M | $3M | — | $3M | $7M | $-3M | — | $-5M |
| EPS (diluted) | $0.47 | $0.04 | — | $0.05 | $0.11 | $-0.04 | — | $-0.08 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $29M | $36M | $51M | $42M | $33M | $23M | $42M | $43M |
| Inventory | $80M | $83M | $82M | $96M | $96M | $94M | $92M | $90M |
| Total current assets | $258M | $250M | $273M | $281M | $275M | $249M | $276M | $299M |
| Total assets | $673M | $651M | $684M | $702M | $707M | $691M | $728M | $769M |
| Long-term debt | $230M | $253M | $279M | $311M | $298M | $309M | $308M | $345M |
| Total liabilities | $396M | $416M | $455M | $494M | $505M | $506M | $542M | $583M |
| Total equity | $228M | $234M | $184M | $166M | $201M | $185M | $148M | $187M |